Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Gains from Investment Securities (2016 - 2025)

Lifecore Biomedical, Inc. \De\ (LFCR) has 15 years of Gains from Investment Securities data on record, last reported at $2.4 million in Q4 2024.

  • For Q4 2024, Gains from Investment Securities rose 3187.67% year-over-year to $2.4 million; the TTM value through Nov 2024 reached $2.9 million, up 1738.98%, while the annual FY2025 figure was -$7.8 million, 43100.0% down from the prior year.
  • Gains from Investment Securities reached $2.4 million in Q4 2024 per LFCR's latest filing, up from $589000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $2.4 million in Q4 2024 and bottomed at -$537000.0 in Q1 2022.
  • Average Gains from Investment Securities over 5 years is $153888.9, with a median of $47500.0 recorded in 2021.
  • Peak YoY movement for Gains from Investment Securities: tumbled 1727.27% in 2022, then surged 19733.33% in 2024.
  • A 5-year view of Gains from Investment Securities shows it stood at -$21000.0 in 2020, then skyrocketed by 433.33% to $70000.0 in 2021, then soared by 102.86% to $142000.0 in 2022, then crashed by 48.59% to $73000.0 in 2023, then surged by 3187.67% to $2.4 million in 2024.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $2.4 million in Q4 2024, $589000.0 in Q3 2024, and -$114000.0 in Q2 2024.